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Abstract
Background—Rapid improvements in hepatitis C virus (HCV) therapy have led to the approval 
of multiple oral direct-acting antiviral (DAA) regimens by the U.S. Food and Drug Administration 
(FDA) for treatment of chronic HCV infection.
Purpose—To summarize published literature on the efficacy and safety of oral DAAs for 
treatment of persons with chronic HCV infection.
Data Sources—MEDLINE and EMBASE from inception through 1 November 2016.
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Study Selection—42 English-language studies from controlled and single-group registered 
clinical trials of adults with HCV infection that evaluated at least 8 weeks of an FDA-approved 
interferon-free HCV regimen that included at least 2 DAAs.
Data Extraction—Two investigators abstracted data on study design, patient characteristics, and 
virologic and safety outcomes sequentially and assessed quality independently.
Data Synthesis—Six DAA regimens showed high sustained virologic response (SVR) rates 
(>95%) in patients with HCV genotype 1 infection without cirrhosis, including those with HIV co-
infection. Effective treatments for HCV genotype 3 infection are limited (2 DAA regimens). 
Patients with hepatic decompensation, particularly those with Child–Turcotte–Pugh class C 
disease, had lower SVR rates (78% to 87%) than other populations. The addition of ribavirin was 
associated with increased SVR rates for certain DAA regimens and patient groups. Overall rates of 
serious adverse events and treatment discontinuation were low (<10% in the general population); 
regimens that included ribavirin had more mild or moderate adverse events than those without.
Limitations—Twenty-three studies had moderate risk of bias (10 were open-label single-group 
trials, 11 had limited information on concealment of the allocation scheme, and 5 had selective 
outcome reporting). All but 1 of the studies were industry-funded. Heterogeneity of interventions 
precluded pooling.
Conclusion—Multiple oral DAA regimens show high rates of safety, tolerability, and efficacy 
for treatment of HCV genotype 1 infection, particularly among persons without cirrhosis.
Primary Funding Source—Patient-Centered Outcomes Research Institute. (PROSPERO: 
CRD42014009711)
In the United States, 3.2 to 5 million people are chronically infected with hepatitis C virus 
(HCV) and are at risk for cirrhosis, liver cancer, and death if untreated (1,2). Infection with 
HCV is the primary indication for liver transplantation and causes more deaths than all other 
notifiable infectious diseases in the United States combined (3, 4). Cure of this infection, 
defined as the absence of detectable HCV RNA in the blood at least 12 weeks after 
treatment completion (sustained virologic response [SVR]), is strongly associated with 
reduced liver-related morbidity and mortality (5, 6). The development of drugs that directly 
inhibit key steps in viral replication has led to availability of several oral HCV treatment 
regimens (7). We systematically reviewed the efficacy and safety of oral interferon-free 
HCV treatment regimens that have been approved by the U.S. Food and Drug 
Administration (FDA) and include at least 2 direct-acting antivirals (DAAs). We also 
assessed the effect of ribavirin on rates of SVR and adverse events. We reviewed phase 2 and 
3 clinical trial data for patients infected with HCV genotypes 1 to 6 and patients previously 
considered difficult to cure with decompensated cirrhosis, HIV infection, renal failure, or 
liver transplantation.
Methods
Data Sources and Searches
We developed a protocol for this systematic review and registered it in PROSPERO 
(CRD42014009711). We searched MEDLINE and EMBASE for literature published in 
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English from inception through 1 November 2016. The search strategy included terms for 
HCV infection and the medications of interest (Figure 1). We also searched 
ClinicalTrials.gov and hand-searched the reference lists of included articles and related 
systematic reviews.
Study Selection
We included English-language, single-group, randomized, controlled trials (RCTs) of adults 
with chronic HCV infection that evaluated at least 8 weeks of an FDA-approved interferon-
free HCV regimen that included at least 2 DAAs. We included trials that used DAA 
combinations—including inhibitors of HCV NS3 protease (grazoprevir, paritaprevir, and 
simeprevir), NS5A (daclatasvir, elbasvir, ledipasvir, ombitasvir, and velpatasvir), and NS5B 
polymerase (sofosbuvir and dasabuvir), as well as the oral antiviral ribavirin—and for which 
the primary outcome was SVR. We excluded studies published only as abstracts; dose-
finding studies; those in which the primary outcome was pharmacokinetics; or those in 
which the regimens included interferon, DAAs that were not FDA-approved, or only 1 DAA 
(for example, sofosbuvir plus ribavirin). Trials were included regardless of participants’ 
cirrhosis, HIV, or liver transplantation status, but trials of limited populations (for example, 
DAA-experienced patients or those of a single race) were excluded.
Data Extraction and Quality Assessment
Two reviewers independently screened titles and abstracts and then the full text of 
potentially eligible articles to identify studies meeting inclusion criteria. Using standardized 
forms, 1 reviewer extracted information from the selected studies about study characteristics, 
design, outcomes, and the funding source. A second reviewer confirmed the accuracy of the 
extractions. Differences were resolved through consensus. Two reviewers independently 
assessed risk of bias for each selected study by using 5 items from the Cochrane risk-of-bias 
tools for RCTs and a Cochrane tool for assessment of risk of bias in nonrandomized trials 
and observational studies (8, 9).
Data Synthesis and Analysis
Detailed evidence tables were generated, and studies were summarized by outcomes. The 
results were organized by genotype and then by the specific population studied. The 
heterogeneity of the interventions precluded quantitative pooling of results.
Role of the Funding Source
The Patient-Centered Outcomes Research Institute (PCORI) funded the study and reviewed 
the report but did not participate in the formulation of the review’s questions, data searches, 
study appraisals, evidence interpretation, or the preparation or approval of the manuscript for 
publication.
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Results
Study and Quality Characteristics
Of 1796 citations evaluated, we included 42 studies published in 40 articles (Figure 1). All 
but 1 of the studies were funded by industry (10). Ten were open-label, single-group studies 
(10–19); 5 had a placebo group with deferred treatment (20–24); 11 evaluated different 
durations of therapies and the addition of ribavirin (for example, 8 vs. 12 weeks or 12 vs. 24 
weeks of therapy with or without ribavirin) (25–35); 5 evaluated the same duration of 
therapy with and without ribavirin (36–39); 6 evaluated different durations with ribavirin 
(40–45); and 3 evaluated different durations of therapy without ribavirin (46–48). Only 2 
studies had an active comparator group receiving an HCV treatment regimen other than that 
being evaluated in the trial (49). Three studies had 48 weeks of posttreatment follow-up, 
whereas the remainder had 12 or 24 weeks of follow-up.
Of the 42 studies, 19 had low risk of bias and 23 had moderate risk. Sources of possible bias 
included single-group design (n = 10), lack of information on sequence generation or 
concealment of the allocation scheme (n = 11), and selective reporting of outcomes (n = 5). 
Because SVR is a highly objective outcome measure, lack of blinding was not considered an 
important threat to validity. Rates of loss to follow-up were low (<10% for all studies).
HCV Genotype 1 Infection
Thirty-two studies enrolled persons with HCV genotype 1 infection (Table; Figure 2; and 
Table 1 of the Supplement, available at Annals.org).
Regimens That Include NS3/4A Protease Inhibitors
Grazoprevir–Elbasvir: Grazoprevir is an NS3 protease inhibitor that is available in a fixed-
dose combination with elbasvir, an NS5A inhibitor. This regimen was studied in 4 
multicenter randomized trials published in 6 articles (11, 20, 21, 25–27). Risk of bias was 
moderate in 3 of these studies due to lack of a comparator group (n = 1) and selective 
reporting (n = 2). Daily grazoprevir-elbasvir for 12 weeks was associated with SVR rates of 
92% and 99% to 100% in treatment-naive and treatment-experienced patients with genotype 
1a and 1b infection, respectively (20, 26, 27). Among patients with genotype 1a but not 
genotype 1b infection, lower SVR rates were associated with pretreatment presence of 
naturally occurring resistance-associated substitutions (RASs) at positions 28, 30, 31, and 93 
of the NS5A region (20, 27). Prolongation of therapy to 16 weeks and addition of ribavirin 
led to SVR among 49 treatment-experienced patients, including all 6 patients with baseline 
NS5A RASs (27). Ribavirin was associated with greater incidence of anemia (3% to 16% vs. 
0%), fatigue, and nausea (25–27). With the exception of patients with genotype 1a infection 
with baseline RASs, the SVR rate was similar in those treated with or without ribavirin. 
Cirrhosis was not associated with lower SVR rates (14, 16).
Paritaprevir–Ritonavir–Ombitasvir and Dasabuvir: Paritaprevir is an NS3 protease 
inhibitor that is coformulated with ritonavir (to provide pharmacologic boosting) and 
ombitasvir (an NS5A inhibitor). For patients with genotype 1 infection, dasabuvir (a non-
nucleoside NS5B polymerase inhibitor) was added. We identified 1 study with low risk of 
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bias that used the two-DAA regimen without dasabuvir (45) and 9 studies (5 with low risk of 
bias and 4 with moderate risk of bias) that used the three-DAA regimen for 12 or 24 weeks 
(12, 13, 22, 23, 37, 38, 40, 41). Moderate risk of bias was due to lack of a comparator group 
(n = 2) and unclear sequence generation and allocation scheme concealment (n = 2). The 
three-DAA regimen without ribavirin yielded lower SVR rates in persons with genotype 1a 
infection (90%) than those with genotype 1b infection (99%); however, with the addition of 
ribavirin, the SVR rate among noncirrhotic patients with genotype 1a infection increased to 
97% (38). Compared with placebo, ribavirin was associated with more anemia, fatigue, 
insomnia, and rash (22, 38). Among cirrhotic patients with genotype 1a infection, the three-
DAA regimen plus ribavirin for 24 weeks led to higher SVR rates than 12 weeks of 
treatment (94.2% vs. 88.6%) (41). High rates of SVR were seen among cirrhotic and 
noncirrhotic patients with genotype 1b infection treated for 12 weeks with the three-DAA 
regimen alone or with ribavirin (97% to 100%) (22, 23, 37, 38, 41, 45).
Simeprevir and Sofosbuvir: Simeprevir is an NS3 protease inhibitor that is used once daily 
in combination with sofosbuvir, a nucleoside analogue NS5B polymerase inhibitor. We 
identified 3 studies using this regimen (14, 28, 46). Risk of bias was moderate in 2 studies 
due to unclear sequence generation (n = 1) and lack of a comparator group (n = 1). When 
used for 12 weeks, the regimen was associated with high rates of SVR (97%) in persons 
with HCV genotype 1a or 1b infection without cirrhosis (46). In this population, 
pretreatment presence of naturally occurring simeprevir RASs at position 80 of the NS3 
region (Q80K) was not associated with lower SVR rates (46). However, lower SVR rates 
were observed among patients with cirrhosis (79% to 88%) and, in this population, the 
presence of the Q80K RAS was associated with lower SVR rates in patients with genotype 
1a infection (74% with Q80K and 92% without) (14).
Regimens That Do Not Include NS3/4A Protease Inhibitors
Daclatasvir and Sofosbuvir: Daclatasvir is an NS5A inhibitor used with sofosbuvir. 
Clinical trial data on this combination are limited but suggest high SVR rates with 12- and 
24-week treatment (96% to 100%), based on data from 2 studies with moderate risk of bias 
(29, 48). Among patients with advanced liver disease, SVR rates were lower (82%) (15).
Ledipasvir–Sofosbuvir: Ledipasvir, an NS5A inhibitor, is coformulated with sofosbuvir as 
a once-daily tablet. Eight studies (4 with low risk of bias and 4 with moderate risk of bias) 
evaluated different treatment durations (8, 12, and 24 weeks) and the addition of ribavirin 
(17, 30–34, 43, 44). Moderate risk of bias was due to lack of a comparator (n = 1) and 
unclear sequence generation or allocation scheme concealment (n = 3). In treatment-naive 
patients, SVR rates were greater than 95% with 12 weeks of treatment, and longer treatment 
did not yield higher rates (30, 31, 33). Although 8 weeks of therapy was assessed in 1 RCT 
and was found to lead to high SVR rates in noncirrhotic persons with pretreatment HCV 
RNA levels less than 6 × 106 IU/mL (33), the most data on efficacy are for 12 weeks. In 
treatment-naive patients, ribavirin was not associated with higher SVR rates regardless of 
cirrhosis status, whereas in treatment-experienced patients, either longer therapy (24 weeks) 
with ledipasvir–sofosbuvir or the addition of ribavirin to the regimen for 12 weeks was 
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associated with higher SVR rates in patients with cirrhosis (97% vs. 96%) (34). The addition 
of ribavirin led to more adverse events, notably anemia, fatigue, and insomnia (31–33).
Velpatasvir–Sofosbuvir: Velpatasvir, a pangenotypic NS5A inhibitor, is coformulated with 
sofosbuvir as a once-daily tablet. This regimen for 12 weeks was associated with high SVR 
rates (97% to 99%) in patients with HCV genotype 1a or 1b infection, including those with 
cirrhosis and prior treatment experience (24). In this placebo-controlled, double-blind trial 
with low risk of bias, the incidence of adverse events was similar in patients receiving 
velpatasvir–sofosbuvir and those receiving placebo.
HCV Genotype 2 Infection
Six studies enrolled patients with HCV genotype 2 infection (Table and Figure 3); 3 studies 
(2 with low risk of bias and 1 with moderate risk of bias) evaluated the fixed-dose 
combination of velpatasvir–sofosbuvir (24, 35, 49), and 3 with moderate risk of bias 
evaluated daclatasvir plus sofosbuvir (15, 29, 48).
Daclatasvir and Sofosbuvir—In the ALLY-2 study, all 13 HIV-infected patients with 
genotype 2 infection who were treated for 12 weeks achieved SVR (48). In another study, 24 
of 26 (92%) treatment-naive, noncirrhotic, HIV-seronegative patients treated for 24 weeks 
with or without ribavirin achieved SVR; 2 patients were lost to follow-up (29).
Velpatasvir–Sofosbuvir—The ASTRAL-1 and ASTRAL-2 studies reported SVR in 237 
of 238 patients (99%) with genotype 2 infection who received velpatasvir–sofosbuvir for 12 
weeks; 1 patient was lost to follow-up (24, 49). Rates of SVR were not affected by cirrhosis 
or prior treatment experience. In an RCT, velpatasvir–sofosbuvir was superior to sofosbuvir 
plus ribavirin (SVR of 99% vs. 94%) and was associated with fewer adverse events (49).
HCV Genotype 3 Infection
Eight studies enrolled patients with HCV genotype 3 infection (Table and Figure 3).
Daclatasvir and Sofosbuvir—In a phase 2 study, 16 of 18 noncirrhotic patients treated 
with or without ribavirin for 24 weeks achieved SVR (29). In the single-group ALLY-3 trial, 
which had moderate risk of bias, 94% to 97% of noncirrhotic treatment-naive and treatment-
experienced patients achieved SVR with 12 weeks of treatment (16). In the same study, 
cirrhosis was associated with a marked reduction in SVR (58% to 69%) (16). The addition 
of ribavirin to the regimen for 12 or 16 weeks in patients with advanced liver disease led to 
SVR in 86% of cirrhotic patients (n = 36) in the ALLY-3+ study, which had moderate risk of 
bias due to unclear sequence generation and allocation scheme (42).
Ledipasvir–Sofosbuvir—In a single-center study with low risk of bias, all 26 treatment-
naive patients treated with ledipasvir– sofosbuvir plus ribavirin for 12 weeks achieved SVR 
(39). The SVR rate was lower without ribavirin (64%) and in treatment-experienced patients 
(82%) (39).
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Velpatasvir–Sofosbuvir—In a phase 3 RCT with 552 patients and low risk of bias, 
velpatasvir–sofosbuvir for 12 weeks (95%) was superior to sofosbuvir plus ribavirin for 24 
weeks (80%) and was associated with fewer adverse events, particularly less anemia (49). 
Lower SVR rates were observed in patients with pretreatment presence of velpatasvir NS5A 
RASs, particularly at position 93 (88%), compared with those without RASs (97%).
HCV Genotype 4 Infection
Twelve studies enrolled persons with HCV genotype 4 infection (Table and Figure 3).
Grazoprevir–Elbasvir—In the C-EDGE study, efficacy of grazoprevir– elbasvir was 
demonstrated among 18 of 18 treatment-naive patients with genotype 4 infection (SVR of 
100%) who received the regimen for 12 weeks; baseline presence of NS5A RASs did not 
affect SVR (20). Among treatment-experienced patients in a randomized trial of 12 or 16 
weeks of the regimen with or without ribavirin, SVR rates were below 95% in all groups 
except patients who received 16 weeks of the regimen with ribavirin (27).
Paritaprevir–Ritonavir–Ombitasvir—In 1 trial with low risk of bias, paritaprevir– 
ritonavir–ombitasvir plus ribavirin resulted in high efficacy (SVR of 100%) in both 
treatment-naive (n = 42) and treatment-experienced (n = 44) patients with genotype 4 
infection (36). The absence of ribavirin was associated with a lower SVR rate (91%).
Simeprevir and Sofosbuvir—In an RCT with moderate risk of bias due to unclear 
sequence generation and allocation scheme concealment, simeprevir plus sofosbuvir was 
associated with SVR in all 43 patients (100%) treated for 12 weeks, including those with 
cirrhosis (n = 23); however, SVR rates were lower in 20 patients treated for 8 weeks (75%) 
(47).
Ledipasvir–Sofosbuvir—In a single-group trial of 21 patients, 95% who received 12 
weeks of ledipasvir–sofosbuvir achieved SVR; the study included few patients with cirrhosis 
(n = 7) or prior treatment experience (n = 8) (10). In a similar trial conducted in France, 41 
of 44 patients (93%) who were treated for 12 weeks achieved SVR (19). No serious adverse 
events were reported in these studies (10, 19).
Velpatasvir–Sofosbuvir—In the ASTRAL-1 RCT, which had low risk of bias, 
velpatasvir–sofosbuvir led to SVR in all 116 treatment-naive and treatment-experienced 
patients (100%) who were treated, including those with cirrhosis (24).
HCV Genotype 5 and 6 Infection
Six studies enrolled persons with HCV genotype 5 and/or 6 infection (18, 20, 24, 27, 35, 39) 
(Figure 3).
Ledipasvir–Sofosbuvir—This combination led to high SVR rates in persons with 
genotype 5 (n = 41; SVR of 95%) and genotype 6 (n = 25; SVR of 96%) infection (18, 39). 
Although the numbers of patients in these subgroups were small, SVR rates were high in 
treatment-experienced patients (≥95%) and those with cirrhosis (89%) (18).
Falade-Nwulia et al. Page 7
Ann Intern Med. Author manuscript; available in PMC 2018 March 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Velpatasvir–Sofosbuvir—In 1 RCT with low risk of bias, patients with genotype 5 (n = 
35) and genotype 6 (n = 41) infection achieved high rates of SVR (97% and 100%, 
respectively) with 12 weeks of treatment; only 1 patient did not achieve SVR (death 
unrelated to treatment) (24).
Subpopulations
Patients With HIV Co-infection—Direct-acting antiviral regimens used for 12 or 24 
weeks showed high SVR rates (91% to 98%) and low adverse event rates (<10%). These 
rates were similar to those observed in persons without HIV (11, 17, 26, 40, 48). Shorter 
therapy (8 weeks) was evaluated in 1 RCT of daclatasvir plus sofosbuvir and led to lower 
rates of SVR (76%) than 12 weeks of therapy (97%) (48).
Patients With Decompensated Cirrhosis—Relatively few patients with 
decompensated liver disease (for example, those with jaundice, ascites, encephalopathy, or 
variceal hemorrhage) have been enrolled in DAA trials. Because of impaired metabolism, 
NS3 protease inhibitors are not recommended (simeprevir) or are contraindicated 
(paritaprevir or grazoprevir) in patients with Child–Turcotte–Pugh class B and C disease. 
These patients have been treated in trials of sofosbuvir plus NS5A inhibitors, including 
daclatasvir, ledipasvir, and velpatasvir (15, 35, 43, 44). In 1 RCT, velpatasvir–sofosbuvir 
with ribavirin for 12 weeks was more effective than velpatasvir–sofosbuvir alone for 12 or 
24 weeks; however, ribavirin was associated with more treatment discontinuation due to 
adverse events (35). Across all studies, rates of serious adverse events were higher in 
patients with decompensated cirrhosis (10% to 52%) than in the general HCV patient 
populations (<10%).
Patients After Liver Transplantation—Four trials evaluated DAAs in patients who had 
undergone liver transplantation. Overall, SVR rates observed in these trials were similar to 
those reported in patients without a transplant (12, 15, 43, 44). However, among liver 
transplant patients with decompensated liver disease due to recurrent HCV infection, SVR 
rates were lower (50% to 80%) and adverse event rates were higher (16% to 75%) than those 
observed in liver transplant patients with compensated cirrhosis or those with minimal liver 
disease (6% to 21%) (12, 43, 44).
Patients With Chronic Kidney Disease—In 2 studies of patients with advanced renal 
dysfunction, including those receiving hemodialysis, high SVR rates were reported in those 
with HCV genotype 1 infection (13, 21). In 1 study with low risk of bias, grazoprevir–
elbasvir for 12 weeks resulted in SVR in 94% of patients (n = 111) (21). In a smaller study 
with moderate risk of bias due to lack of a comparator group, a regimen of paritaprevir–
ritonavir–ombitasvir and dasabuvir was effective (SVR of 90%), but ribavirin, which was 
used for patients with genotype 1a infection, was poorly tolerated and was discontinued due 
to adverse events in 8 of 14 patients (48).
Discussion
Multiple interferon-free, oral DAA regimens are available for treatment of chronic HCV 
infection. We found high SVR rates for all FDA-approved DAA regimens, with some 
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evidence of variable response influenced by specific patient and virus characteristics. Rates 
of serious adverse events (<10%), loss to follow-up (<10%), and treatment discontinuation 
(<5%) were low even in patients with comorbid conditions, such as HIV infection and 
cirrhosis.
The evidence was robust for persons with genotype 1 infection, which is the most common 
genotype worldwide, infecting approximately 84 million persons (50). We reviewed 6 
distinct DAA regimens for genotype 1 infection, with SVR rates greater than 95% for most 
drug combinations and patient populations. Our findings represent an important update of 
other systematic reviews of DAA regimens with and without interferon for treatment of 
HCV genotype 1 infection, which reported SVR rates in the range of 95% (50, 51) and 92% 
(52). The high treatment response rates in persons with genotype 1 infection are particularly 
important in light of the historically poor SVR rates observed with interferon in this 
population.
In contrast, fewer DAA regimens are available and effective for the treatment of HCV 
genotype 3 infection, which is the second most prevalent HCV genotype globally, infecting 
approximately 54 million persons. Our findings indicate that the most effective DAA 
regimens for patients who have genotype 3 infection without cirrhosis are sofosbuvir plus 
the NS5A inhibitors velpatasvir or daclatasvir for 12 weeks, whereas higher SVR rates were 
observed with velpatasvir–sofosbuvir in patients with cirrhosis. This agrees with recent 
systematic reviews, identified through MEDLINE searches from 2014 to 2016, that 
identified velpatasvir–sofosbuvir as the most effective treatment for genotype 3 infection 
(51, 52). Our findings also suggest that lower SVR rates were achieved in patients with 
compensated and decompensated cirrhosis, prior treatment experience, or NS5A RASs; the 
addition of ribavirin and longer treatment duration were associated with higher SVR rates in 
these patient groups (42, 53).
Although relatively few studies enrolled patients with genotype 2, 4, 5, or 6 infection, high 
rates of SVR (>92%) were observed for all regimens administered for at least 12 weeks. 
Rates of SVR were particularly high (99%) for patients with genotype 2, 4, 5, or 6 infection 
treated with velpatasvir–sofosbuvir (24). For treatment of genotype 4 infection, all but 1 of 
the DAA regimens (paritaprevir–ritonavir–ombitasvir) led to high SVR rates (93% to 100%) 
without ribavirin and were associated with minimal adverse effects in treatment-naive 
patients.
Oral DAA regimens also showed high SVR rates and minimal adverse events in patient 
populations that were poorly responsive or could not be treated with interferon, including 
those with HIV co-infection, decompensated cirrhosis, severe chronic kidney disease, and a 
liver transplant. Patients co-infected with HIV and HCV and those receiving 
immunosuppressive agents after liver transplantation had SVR rates similar to those of 
persons without immune dysfunction, suggesting that oral DAAs mitigate the effect of an 
impaired HCV immune response (54–56). Direct-acting antiviral options for persons with 
severe chronic kidney disease remain limited, and although high SVR rates (85% to 100%) 
were observed in 2 RCTs for persons with HCV genotype 1 infection, no trials were 
identified in persons with genotype 2 or 3 infection, for whom interferon is still 
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recommended (57). Treatment options also remain limited in patients with decompensated 
liver disease. Current NS3 protease inhibitors are hepatically metabolized and are 
contraindicated in this population; as such, trials have been restricted to sofosbuvir plus 
NS5A inhibitors. The evidence indicates that these regimens provide high rates of SVR 
(>85%), but serious adverse events are common (10% to 52%). In addition, questions 
remain with regard to the long-term clinical benefit of cure of HCV infection in persons with 
severe liver dysfunction.
Across multiple trials, our findings indicate that ribavirin continues to have a role in 
maximizing SVR rates in certain patients, including those with genotype 1a or 3 infection, 
cirrhosis, or prior treatment experience. Clinical trials for patients with decompensated 
cirrhosis and a liver transplant have also largely included ribavirin. Although ribavirin was 
associated with an increase in anemia, fatigue, and insomnia, the rates of serious adverse 
events and treatment discontinuation were similar in patients treated with and without it.
Limitations of this study include the fact that safety data from clinical trials may not fully 
represent patient experience in clinical practice. Persons with chronic hepatitis B virus 
infection were excluded from trials, and the risk for hepatitis B virus reactivation was not 
examined. We also included noncontrolled trials; however, spontaneous cure of HCV 
infection is rare. Most of the studies were industry-funded; such studies are more likely to be 
published if results are favorable (58), but we are not aware of large, unpublished studies in 
this field and the risk of bias with the objective outcome of SVR is low. The heterogeneity of 
the interventions studied also prevented quantitative pooling of results, and the relatively 
short follow-up limits our ability to comment on late relapse of HCV infection. Several 
studies were also population-specific, thus limiting generalizability of findings to all 
patients. Given the multitude of effective oral DAA regimens with similar rates of SVR and 
adverse events, RCTs will be needed to determine the best HCV treatments for different 
patient populations. One such trial, the PRIORITIZE study (ClinicalTrials.gov: 
NCT02786537), is under way in persons with genotype 1 infection (59).
Finally, our systematic review is limited by the rapidly evolving HCV treatment landscape 
and the inability to include all DAA regimens in ongoing or recently completed clinical 
trials that we identified on ClinicalTrials.gov (Table 7 of the Supplement). These ongoing 
clinical trials include 2 novel nucleotide analogue NS5B polymerase inhibitors, MK-3682 
and AL-335, which are being evaluated in combination with approved NS3 protease 
inhibitors and novel NS5A inhibitors (ruzasvir and odalasvir), as well as 2 novel 
pangenotypic NS3 protease inhibitors, voxilaprevir and glecaprevir, which are being 
evaluated in combination with approved (sofosbuvir–velpatasvir–voxilaprevir) and novel 
(glecaprevir–pibrentasvir) DAAs (60).
In conclusion, oral DAA regimens that are highly efficacious, well-tolerated, and relatively 
short in duration are now available for all HCV genotypes and for patient populations 
historically considered difficult to cure. The ease of dosing, safety profile, and effectiveness 
of these agents provide an opportunity to expand the number of patients who can be treated 
for HCV infection and the pool of treating providers. Rapid developments in oral DAA 
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therapies can be beneficial only if they are linked to efforts to improve rates of HCV 
detection, linkage to care, and access to DAA therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Summary of evidence search and selection
FDA = U.S. Food and Drug Administration; SVR = sustained virologic response.
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Figure 2. HCV genotype 1a and 1b SVR12 rates and 95% CIs, by oral DAA regimen and clinical 
trial
DAA = direct-acting antiviral; DAV = dasabuvir; DCV = daclatasvir; EBV = elbasvir; GZP 
= grazoprevir; HCV = hepatitis C virus; LDV = ledipasvir; OBV = ombitasvir; PLAC = 
placebo; PTV–r = paritaprevir–ritonavir; RBV = ribavirin; SIM = simeprevir; SOF = 
sofosbuvir; SVR12 = sustained virologic response at 12 wk; VEL = velpatasvir.
Falade-Nwulia et al. Page 17
Ann Intern Med. Author manuscript; available in PMC 2018 March 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. HCV genotype 2 to 6 SVR12 rates and 95% CIs, by oral DAA regimen and clinical trial
DAA = direct-acting antiviral; DAV = dasabuvir; DCV = daclatasvir; EBV = elbasvir; GZP 
= grazoprevir; HCV = hepatitis C virus; LDV = ledipasvir; OBV = ombitasvir; PTV–r = 
paritaprevir–ritonavir; RBV = ribavirin; SIM = simeprevir; SOF = sofosbuvir; SVR12 = 
sustained virologic response at 12 wk; VEL = velpatasvir.
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Table
Summary of Clinical Trial Outcomes, by Genotype and Regimen
Regimen, by Genotype Studies Included Summary of Findings Risk of Bias
HCV-1
 GZP–EBV 4 RCTs (6 articles) (n = 
1644)
SVR with 12 wk ≥92% in TN and TE patients with and 
without cirrhosis, HIV co-infection, and chronic kidney 
disease. SVR with 12 wk in patients with genotype 1a 
infection varied according to baseline NS5A RAS status 
(present, 58%–60%; absent, 98%–99%).
Low (n = 3)
Moderate (n = 3)
 PTV–r–OBV–DAV ± RBV 10 RCTs (n = 2702) SVR with 12 wk of 97%–100% in TN and TE patients 
with genotype 1b infection with and without cirrhosis. In 
noncirrhotic patients with genotype 1a infection, SVR with 
12 wk varied according to RBV use (with, 97%; without, 
90%). In cirrhotic patients, SVR with 12 wk varied 
according to treatment duration (12 wk, 87%; 24 wk, 
94%). SVR with 12 wk ± RBV in patients with HIV 
infection, 94%; a liver transplant, 97%; and chronic kidney 
disease, 85%.
Low (n = 6)
Moderate (n = 4)
 SIM + SOF ± RBV 2 RCTs (n = 478)
1 single-group study (n = 
103)
SVR with 12 wk varied according to cirrhosis and 
treatment experience (TN and no cirrhosis, 97%; TN and 
cirrhosis, 91%; TE and cirrhosis, 79%). SVR was lower in 
patients with cirrhosis and the NS3 RAS Q80K at baseline.
Low (n = 1)
Moderate (n = 2)
 DCV + SOF 2 RCTs (n = 238)
1 single-group study (n = 
168)
SVR with 12 or 24 wk in TN and TE patients, including 
those with HIV co-infection, 95%–100%. SVR with 12 wk 
+ RBV in patients with a liver transplant, 95%; in those 
with decompensated cirrhosis, 82%.
Moderate (n = 3)
 LDV–SOF ± RBV 7 RCTs (n = 2718)
1 single-group study (n = 
327)
SVR with 12 wk ≥95% in TN patients with and without 
cirrhosis. In TE patients with cirrhosis, SVR varied 
according to RBV use and treatment duration (12 wk + no 
RBV, 86%; 12 wk + RBV, 97%; 24 wk + no RBV, 96%). 
SVR with 12 wk + RBV in patients with decompensated 
cirrhosis, 85%–87%.
Low (n = 4)
Moderate (n = 4)
 VEL–SOF ± RBV 2 RCTs (n = 600) SVR with 12 wk >98% in TN and TE patients with and 
without cirrhosis. SVR with 12 wk + RBV in patients with 
decompensated cirrhosis, 94%.
Low (n = 1)
Moderate (n = 1)
HCV-2
 DCV + SOF 2 RCTs (n = 45)
1 single-group study (n = 5)
SVR with 12 or 24 wk of 92%–100% in TN and TE 
patients, including those with HIV co-infection. SVR with 
12 wk + RBV in 5 patients with decompensated cirrhosis, 
80%.
Moderate (n = 3)
 VEL–SOF ± RBV 3 RCTs (n = 407) SVR with 12 wk of 99%–100% in TN and TE patients 
with and without cirrhosis. SVR with 12 wk ± RBV in 8 
patients with decompensated cirrhosis, 100%.
Low (n = 2)
Moderate (n = 1)
HCV-3
 DCV + SOF ± RBV 3 RCTs (n = 107)
2 single-group studies (n = 
169)
SVR with 12 wk varied according to cirrhosis status 
(TN/TE + no cirrhosis, 94%–97%; TN/TE + cirrhosis, 
58%–69%). SVR with 12 or 16 wk + RBV in patients with 
cirrhosis, 83%–89%.
Moderate (n = 5)
 LDV–SOF ± RBV 1 RCT (n = 26) SVR varied according to RBV use (12 wk + RBV, 100%; 
12 wk + no RBV, 64%).
Low (n = 1)
 VEL–SOF ± RBV 2 RCTs (n = 591) SVR with 12 wk of 95% in TN and TE patients with and 
without cirrhosis. SVR in patients with decompensated 
cirrhosis varied according to RBV use (12 wk + RBV, 
85%; 12 wk + no RBV, 50%; 24 wk + no RBV, 50%).
Low (n = 1)
Moderate (n = 1)
HCV-4
 GZP–EBV ± RBV 2 RCTs (n = 63)
1 single-group study (n = 
28)
SVR with 12 wk of 96%–100% in TN and TE patients 
with and without cirrhosis, including those with HIV co-
infection.
Moderate (n = 3)
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Regimen, by Genotype Studies Included Summary of Findings Risk of Bias
 PTV–r–OBV ± RBV 1 RCT (n = 135) SVR varied according to RBV use in TN and TE patients 
without cirrhosis (12 wk + RBV, 100%; 12 wk + no RBV, 
91%).
Low (n = 1)
 SIM + SOF 1 RCT (n = 63) SVR with 12 wk of 100% in TN and TE patients with and 
without cirrhosis.
Moderate (n = 1)
 LDV–SOF ± RBV 2 RCTs (n = 41)
3 single-group studies (n = 
74)
SVR with 12 wk of 93%–95% in TN and TE patients with 
and without cirrhosis. SVR with 12 wk + RBV in 7 
patients with decompensated cirrhosis before and after 
liver transplantation, 0%–100%.
Low (n = 2)
Moderate (n = 3)
 VEL–SOF ± RBV 2 RCTs (n = 146) SVR with 12 wk of 100% in TN and TE patients with and 
without cirrhosis. SVR with 12 wk ± RBV in 6 patients 
with decompensated cirrhosis, 100%.
Low (n = 1)
Moderate (n = 1)
HCV-5
 LDV–SOF 1 single-group study (n = 
41)
SVR with 12 wk of 95% in TN and TE patients with and 
without cirrhosis.
Moderate (n = 1)
 VEL–SOF 1 RCT (n = 35) SVR with 12 wk of 97% in TN and TE patients with and 
without cirrhosis.
Moderate (n = 1)
HCV-6
 LDV–SOF 1 single-group study (n = 
25)
SVR with 12 wk of 96% in TN and TE patients with and 
without cirrhosis.
Moderate (n = 1)
 VEL–SOF 2 RCTs (n = 42) SVR with 12 wk of 100% in TN and TE patients with and 
without cirrhosis. SVR with 24 wk in 1 patient with 
decompensated cirrhosis, 100%.
Low (n = 1)
Moderate (n = 1)
DAV = dasabuvir; DCV = daclatasvir; EBV = elbasvir; GZP = grazoprevir; HCV = hepatitis C virus; LDV = ledipasvir; OBV = ombitasvir; PTV–r 
= paritaprevir–ritonavir; Q80K = position 80 of the NS3 region; RAS = resistance-associated substitution; RBV = ribavirin; RCT = randomized, 
controlled trial; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; TE = treatment-experienced; TN = treatment-naive; 
VEL = velpatasvir.
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